Ursprung des Netzwerks ersten Grades von Les Mintzmyer
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Subsidiary | Pharmaceuticals: Major | 2 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Les Mintzmyer
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| CELGENE | Biotechnology | Corporate Officer/Principal | |
| COMPUGEN LTD. | Biotechnology | Director/Board Member | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| TRANSGENE | Biotechnology | Director/Board Member | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal | |
| Aventis, Inc. | Chief Tech/Sci/R&D Officer | ||
| SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member | |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Executive Officer | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member | |
Rhone Poulenc Rorer
 Rhone Poulenc Rorer Chemicals: SpecialtyProcess Industries Part of Solvay SA, Rhone Poulenc Rorer is a French pharmaceutical company that manufactures and distributes pharmaceutical products. | Chemicals: Specialty | Corporate Officer/Principal | |
| Boston College | College/University | Undergraduate Degree | |
| Massachusetts College of Pharmacy & Health Science | College/University | Undergraduate Degree | |
| MEDIVATION INC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Corporate Officer/Principal | |
| University of Nice Sophia Antipolis | College/University | Doctorate Degree | |
| Sanofi-Aventis Pharmaceuticals | Corporate Officer/Principal | ||
Synergie Lyon Cancer
 Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Miscellaneous Commercial Services | President | |
| European Organisation for Research & Treatment of Cancer | Director/Board Member | ||
| VERASTEM, INC. | Biotechnology | Corporate Officer/Principal | |
International Drug Development Institute SA
 International Drug Development Institute SA Miscellaneous Commercial ServicesCommercial Services International Drug Development Institute SA engages in the provision of biostatistics and electronical-clinical solutions for phase I-IV clinical trials. It offers oncology clinical research, consultancy, clinical data management, data standards implementation and randomization services. The company was founded by Marc Buyse in 1991 and is headquartered in Louvain-la-Neuve, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| ADC THERAPEUTICS SA | Pharmaceuticals: Major | Director/Board Member | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member | |
| PIERIS PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Institut de Recherches Internationales Servier
 Institut de Recherches Internationales Servier Miscellaneous Commercial ServicesCommercial Services Part of Servier SAS, Institut de Recherches Internationales Servier is a French company that provides scientific research and development services. The company is based in Suresnes, France. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Finch Research & Development LLC
 Finch Research & Development LLC Pharmaceuticals: MajorHealth Technology Part of Finch Therapeutics Group, Inc., Finch Research & Development LLC provides biopharmaceutical services. The company is based in Cambridge, MA. Finch Research & Development was acquired by Finch Therapeutics, Inc. on October 23, 2017. | Pharmaceuticals: Major | Chief Operating Officer | |
| FINCH THERAPEUTICS GROUP, INC. | Medical/Nursing Services | Chief Operating Officer | |
NETRIS Pharma SAS
 NETRIS Pharma SAS BiotechnologyHealth Technology NETRIS Pharma SAS develops targeted therapies for the treatment of cancer. The company is based in Lyon, France. The French company was founded in 2008 by Patrick Mehlen, Agnès Bernet. Patrick Mehlen has been the CEO since 2008. | Biotechnology | Chairman | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Micromet Inc. | Corporate Officer/Principal | ||
Theravectys SAS
 Theravectys SAS BiotechnologyHealth Technology Theravectys SAS provides biotechnology research services. It is working on the development of a therapeutic vaccine against HIV. The company was founded on May 17, 2005 and is headquartered in Paris, France. | Biotechnology | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 23 |
| Frankreich | 9 |
| Belgien | 4 |
| Israel | 2 |
| Vereinigtes Königreich | 2 |
Sektoral
| Health Technology | 25 |
| Consumer Services | 4 |
| Commercial Services | 4 |
| Process Industries | 3 |
| Health Services | 2 |
Operativ
| Director/Board Member | 18 |
| Corporate Officer/Principal | 12 |
| Independent Dir/Board Member | 10 |
| Chief Operating Officer | 3 |
| Undergraduate Degree | 2 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Jean Bizzari | 24 |
| Joseph Lobacki | 15 |
- Börse
- Insiders
- Les Mintzmyer
- Unternehmensverbindungen
